Combating COVID-19 with integrated traditional Chinese and Western medicine in China.

Abstract

COVID-19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world. China has achieved rapid containment of this highly infectious disease following the principles of early detection, early quarantine and early treatment with integrated traditional Chinese and Western medicine. The inclusion of traditional Chinese medicine (TCM) in the Chinese protocol is based on its successful historic experience in fighting against pestilence. Current findings have shown that the Chinese medicine can reduce the incidence of severe or critical events, improve clinical recovery and help alleviate symptoms such as cough or fever. To date there are over 133 ongoing registered clinical studies on TCM/integrated traditional Chinese and Western medicine. The three Chinese patent medicines (Lianhua Qingwen Keli/Jiaonang (Forsythiae and Honeysuckle Flower Pestilence-Clearing Granules/Capsules), Jinhua Qinggan Keli (Honeysuckle Flower Cold-Relieving Granules) and Xuebijing (Stasis-Resolving & Toxin-Removing) Injection were officially approved by the National Medical Products Administration to list COVID-19 as an additional indication. The pharmacological studies have suggested that Chinese medicine is effective for COVID-19 probably through its host-directed regulation and certain antiviral effects.

• Authors: Liqiang Ni, Lili Chen, Xia Huang, Chouping Han, Jianrong Xu, Hong Zhang, Xin Luan, Yongfang Zhao, Jianguang Xu, Weian Yuan, Hongzhuan Chen
• Journal: Acta pharmaceutica Sinica. B (Acta Pharm Sin B) Vol. 10 Issue 7 Pg. 1149-1162 (Jul 2020) ISSN: 2211-3835 [Print] Netherlands
• PMID: 32834946 (Publication Type: Journal Article, Review)
• Copyright: © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.